EMEA-002559-PIP02-19
Key facts
| Active substance |
Anti-neonatal Fc receptor human monoclonal antibody
|
| Therapeutic area |
Other
|
| Decision number |
P/0117/2020
|
| PIP number |
EMEA-002559-PIP02-19
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of myasthenia gravis
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Janssen-Cilag International NV
Tel. +32 1460 2111 E-mail: contact@janssen-emea.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|